Picoquant invests in Fluobrick Solutions to simplify access to single molecule research
PicoQuant GmbH announces its investment in FluoBrick Solutions GmbH, a newly founded Berlin-based start-up focused on giving life…
Scientists unveil new obesity drug that reprograms fat and energy use
Details of a new drug that aims to treat the underlying causes of obesity are being presented at…
Breakthroughs in diagnosis and therapy for transthyretin amyloidosis
Transthyretin amyloidosis (ATTR) is caused by the misfolding and aggregation of the transthyretin (TTR) protein, leading to multi-organ…